Somewhat Positive Press Coverage Somewhat Unlikely to Affect Ocular Therapeutix (OCUL) Stock Price
Media coverage about Ocular Therapeutix (NASDAQ:OCUL) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocular Therapeutix earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.0800615272145 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
OCUL has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Ocular Therapeutix in a research note on Monday, October 23rd. They issued a “buy” rating and a $12.00 price target on the stock. Zacks Investment Research cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. ValuEngine lowered shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, November 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Monday, September 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.67.
Shares of Ocular Therapeutix (NASDAQ:OCUL) traded down $0.12 on Friday, reaching $4.18. 709,700 shares of the company’s stock were exchanged, compared to its average volume of 876,790. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39. Ocular Therapeutix has a twelve month low of $4.11 and a twelve month high of $11.91.
Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, meeting analysts’ consensus estimates of ($0.54). The firm had revenue of $523.00 million during the quarter, compared to the consensus estimate of $0.52 million. Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.39) EPS. analysts forecast that Ocular Therapeutix will post -2.37 earnings per share for the current fiscal year.
In related news, Chairman Amarpreet Sawhney purchased 19,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was bought at an average cost of $5.18 per share, for a total transaction of $98,420.00. Following the completion of the transaction, the chairman now directly owns 696,390 shares in the company, valued at $3,607,300.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 26.10% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-ocular-therapeutix-ocul-stock-price/1724426.html.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.